Enhancing Anti-Cancer Therapy with Selective Autophagy Inhibitors by Targeting Protective Autophagy

Area of Science:

• Cell Biology
• Oncology
• Pharmacology

Background:

• Autophagy is a vital cellular process for maintaining homeostasis by degrading damaged components.
• Dysregulated autophagy is implicated in various diseases, notably cancer, where it exhibits complex, dual roles.
• The cytoprotective functions of autophagy are crucial for resistance to diverse cancer therapies.

Purpose of the Study:

• To review the genetic and pharmacological modulation of autophagy-related proteins in cancer.
• To explore the therapeutic benefits of targeting autophagy in cancer treatment.
• To summarize the efficacy of combining autophagy inhibitors with chemotherapeutics in preclinical and clinical settings.

Main Methods:

• Review of literature on genetic and pharmacological perturbations of autophagy-related proteins.
• Analysis of preclinical data from cancer animal models evaluating autophagy inhibitors.
• Examination of clinical trial data for combination therapies involving autophagy inhibitors and chemotherapeutics.

Main Results:

• Autophagy inhibitors are being developed to target the autophagic process directly for cancer treatment.
• Preclinical studies demonstrate the efficacy of autophagy inhibitors in various cancer models.
• Combination therapies of autophagy inhibitors with chemotherapeutics are under active clinical investigation.

Conclusions:

• Targeting autophagy offers a promising strategy to overcome resistance to cancer therapies.
• Combination therapies with autophagy inhibitors and chemotherapeutics hold potential for improving clinical outcomes.
• Further understanding of cytoprotective autophagy inhibitors can enhance cancer treatment efficacy and overcome drug resistance.